Condition

Antiretroviral Therapy

ClinicalTrials.gov condition label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov condition label, found in 24 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials24
Recruiting2
Common interventions25
Lead sponsors shown15
Advertisement

Clinical trials

24 shown
Impacts of HIV Treatment Regimens on Archived Drug ResistanceNCT07643948 · 2025-10-01
RECRUITING
Effectiveness and Safety of Darunavir/Cobicistat Plus Lamivudine Compared With Darunavir/Cobicistat Plus Tenofovir Alafenamide/Emtricitabine in Virologically Suppressed People Living With HIV at 24 and 48 Weeks of Follow-upNCT07678268 · 2025-07-10
RECRUITING
Intestinal Tissue-Resident Memory T Cells and HIV-1 Persistence During Antiretroviral TherapyNCT07656077 · 2026-08-01
NOT_YET_RECRUITING
Enhancing Communication on Relationship Preservation, Safer Conception and PrEP to Promote HIV Testing in UgandaNCT06647797 · 2023-09-15
COMPLETED
First in Human Study of TLC-ART 101 (ACTU 2001)NCT05850728 · 2023-04-01
COMPLETED
Next Generation Ingestible Sensors for Medication Adherence MeasurementNCT05592613 · 2023-02-06
COMPLETED
HIV Transmission in the Era of Scaling up Antiretroviral Therapy in EthiopiaNCT05652400 · 2022-07-01
COMPLETED
Survey of Procedures and Resources for Initiating Treatment of HIV in Africa-South AfricaNCT04170374 · 2020-11-01
COMPLETED
Survey of Procedures and Resources for Initiating Treatment of HIV in Africa-ZambiaNCT04470011 · 2020-09-15
COMPLETED
Continuation of Protease-Inhibitor Based Second-Line Therapy vs. Switch to B/F/TAF in Virologically Suppressed AdultsNCT04311957 · 2020-09-01
UNKNOWN
Survey of Procedures and Resources for Initiating Treatment of HIV in Africa-MalawiNCT04468399 · 2020-05-21
COMPLETED
Revised Simplified Algorithm for Treatment Eligibility for HIV (SLATEII)NCT03315013 · 2018-03-14
COMPLETED
Improving Clinic Attendance for Medication Collection Among HIV Positive Individuals in NepalNCT03367130 · 2017-10-14
COMPLETED
Evaluation of a Simplified Strategy for the Long-term Management of HIV Infection (Simpl'HIV)NCT03160105 · 2017-05-19
COMPLETED
Long Term Outcomes of Therapy in Women Initiated on Lifelong ART Because of Pregnancy in DR CongoNCT03048669 · 2016-11-01
COMPLETED
Smart Linkage-to-HIV Care Via a Smartphone AppNCT02756949 · 2015-10-01
COMPLETED
Antiretroviral Treatment Outcomes in HIV-HBV Co-infected Patients in Southern AfricaNCT02060162 · 2013-10-01
COMPLETED
Timely Initiation of HIV Antiretroviral Therapy Among Those Who Delay/DeclineNCT02086630 · 2012-05-01
COMPLETED
Mobile Phone Technology for Prevention of Mother-to-Child Transmission of HIV: Acceptability, Effectiveness, and Cost (Kenya)NCT01645865 · 2011-05-01
COMPLETED
Raltegravir Switch for Toxicity or Adverse EventsNCT00958100 · 2009-08-01
COMPLETED
The Impact of Short Message Services (SMS) on ARV Adherence in Western KenyaNCT01058694 · 2007-06-01
COMPLETED
Unboosted Atazanavir as Initial ART Therapy in ChinaNCT01459575 · 2005-07-01
COMPLETED
Efavirenz to Nevirapine Switch and Low-Density Lipoprotein (LDL)-DyslipidemiaNCT00405171 · 2003-06-01
COMPLETED
Effectiveness of Raltegravir-Based Antiretroviral Therapy in HIV-HCV Coinfected Liver Transplant RecipientsNCT02995824 · 2002-01-01
COMPLETED

Common interventions

Interviews with service providersOTHER3Routine medical record data collectionOTHER3Abacavir freeDRUG1B/F/TAFDRUG1Biktarvy for antiretroviral therapy (ART)DRUG1Colonic Mucosal BiopsiesPROCEDURE1Continuation of boosted PIDRUG1Continuous quality improvementOTHER1ControlBEHAVIORAL1Dual therapy: darunavir/cobicistat + lamivudineDRUG1Exposure to antiretroviral therapyOTHER1Heart to HeartBEHAVIORAL1HOPE Clinical Communication CampaignBEHAVIORAL1InterventionBEHAVIORAL1Lamivudine Abacavir RaltegravirDRUG1Mobile phone reminderBEHAVIORAL1NevirapineDRUG1Next-generation Reader and ID-Cap SystemDEVICE1Patient-centered monitoringOTHER1Raltegravir-based antiretroviral therapyOTHER1Short Message Services to Support ARV therapy adherenceBEHAVIORAL1SLATE IIPROCEDURE1SmartphoneDEVICE1Smartphone applicationOTHER1Standard of careOTHER1

Leading sponsors

Boston University 4 Albert Einstein College of Medicine 1 ANRS, Emerging Infectious Diseases 1 Brigham and Women's Hospital 1 Calmy Alexandra 1 Catholic University of the Sacred Heart 1 Children's Mercy Hospital Kansas City 1 Chinese University of Hong Kong 1 Elizabeth Glaser Pediatric AIDS Foundation 1 Georgetown University 1 Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic 1 Hospital Clinic of Barcelona 1 Instituto Mexicano del Seguro Social 1 Lund University 1 National Center for AIDS/STD Control and Prevention, China CDC 1

Trial status mix

COMPLETED20
RECRUITING2
NOT_YET_RECRUITING1
UNKNOWN1

Phase mix

NA7
PHASE44
PHASE12
PHASE21
PHASE31
Advertisement

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.